ARID1A and cancer: Similarly, the research "KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency"[25] published on January 8, 2025, highlighted the potential of targeting the KLF5-ARID1A axis in cancer cells.